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Cutaneous LymphomaContentsErratum xiPreface: Cutaneous Lymphoma xiiiElise A. OlsenEvaluation, Diagnosis, and Staging of Cutaneous Lymphoma 643Elise A. OlsenPrimary cutaneous lymphomas (PCLs) are an extremely heterogeneous group of
non-Hodgkin lymphomas that manifest in the skin. Their diagnosis is complex and
based on clinical lesion type and evaluation of findings on light microscopic exam-
ination, immunohistochemistry, and molecular analysis of representative skin bi-
opsies. The evaluation, classification, and staging system is unique for mycosis
fungoides (MF) and Se´zary syndrome (SS), the most common subtypes of cuta-
neous T-cell lymphoma (CTCL) versus the other subtypes of Non-MF/Non-SS
CTCL and the subtypes of cutaneous B-cell lymphoma (CBCL). Since current treat-
ment is stage-based, it is particularly important that the correct diagnosis and stage
be ascertained initially. The purpose of this article is to review the current evaluation,
diagnosis, classification, staging, assessment techniques, and response criteria for
the various types of both T-cell and B-cell PCLs.Pathologic Diagnosis of Cutaneous Lymphomas 655Werner Kempf and Christina MitteldorfPrimary cutaneous lymphomas comprise a prognostically heterogeneous group of
lymphocytic skin neoplasms, which display a broad spectrum of clinical, histologic,
immunophenotypic, and genetic features. The histopathological examination plays
an essential role and is often the starting point in the diagnostic workup of cutaneous
lymphomas. In most cases, the histopathological and the phenotypic analysis alone
are limited to provide a list of differential diagnoses. As a consequence of overlap-
ping clinical, histologic, phenotypic, and genetic features among several entities of
cutaneous lymphomas, the clinicopathological correlation is of utmost importance
to achieve the final diagnosis.Skin-Directed Therapies in Cutaneous T-Cell Lymphoma 683Cuong V. Nguyen and Kimberly A. BohjanenEarly stage mycosis fungoides represents the most common clinical presentation of
cutaneous lymphoma, with skin-directed therapies long established in its treatment.
These therapies continue to change as new treatment regimens emerge. Other skin-
directed treatments include light and radiation therapy. Therapies with higher levels
of evidence and less systemic toxicity are usually preferred as first-line treatment.
However, even these established therapies, like topical corticosteroids and carmus-
tine, lack randomized clinical trials to establish their efficacy. Research is also
needed to further define the role of combination topical therapies and how skin-
directed therapies can be used as adjuvants to systemic medications.
ContentsviPhototherapy of Mycosis Fungoides 697Emmilia Hodak and Lev PavlovskyTherapies based on ultraviolet light have long been established in mycosis fungoides
(MF). They have traditionally includedwhole-body ultraviolet light B, both broad-band
and narrow-band, and psoralen plus ultraviolet A. Phototherapymay be applied alone
in early stageMF or in combination with systemic therapy in refractory early stageMF
and advanced MF. This article reviews the most frequently used forms of photother-
apy for MF with emphasis on efficacy, safety, and practical considerations.Radiation Therapy for Cutaneous T-Cell Lymphomas 703Daniel J. Tandberg, Oana Craciunescu, and Chris R. KelseyRadiation therapy is an extraordinarily effective skin-directed therapy for cutaneous
T-cell lymphomas. Lymphocytes are extremely sensitive to radiation and a complete
response is generally achieved even with low doses. Radiation therapy has several
important roles in the management of mycosis fungoides. For the rare patient with
unilesional disease, radiation therapy alone is potentially curative. For patients
with more advanced cutaneous disease, radiation therapy to local lesions or to
the entire skin can effectively palliate symptomatic disease and provide local dis-
ease control. Compared with other skin-directed therapies, radiation therapy is
particularly advantageous because it can effectively penetrate and treat thicker pla-
ques and tumors.The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma 715Auris O. Huen and Ellen J. KimRetinoids are natural and synthetic vitamin A analogs with effects on cell proliferation,
differentiation, and apoptosis. They have significant activity in hematologic malig-
nancies and have been studied extensively in cutaneous T-cell lymphoma. Retinoids
bind to nuclear receptors and exert their effects through moderation of gene expres-
sion.Retinoicacid receptorandretinoicX receptorexert regulatoryactivity invivo,bind-
ing to distinct ligands. Studies investigating systemic retinoids as monotherapy and in
combinationwith other agents active against cutaneous lymphoma are reviewed. Side
effects associated with retinoids include teratogenicity, dyslipidemias, and hypothy-
roidism, which should be carefully monitored in patients receiving treatment.The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma 731Natalie Spaccarelli and Alain H. RookInterferons are polypeptides that naturally occur in the human body as a part of the
innate immune response. By harnessing these immunomodulatory functions, syn-
thetic interferons have shown efficacy in combating various diseases including cuta-
neous T-cell lymphoma. This article closely examines the qualities of interferon alfa
and interferon gamma and the evidence behind their use in the 2most common types
of cutaneous T-cell lymphomas, namely, mycosis fungoides and Se´zary syndrome.Methotrexate and Pralatrexate 747Gary S. Wood and Jianqiang WuThis article reviewsmethotrexate and the more potent, related compound, pralatrex-
ate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides,
Contents viiSe´zary syndrome, and CD30+ lymphoproliferative disorders. Although these folate
antagonists are traditionally viewed as antiproliferative cell cycle inhibitors, it is
recognized that they inhibit DNA methylation, providing a rationale for their use as
epigenetic regulators and cell proliferation inhibitors. The underlying mechanisms
are outlined and key supporting data are presented, followed by a brief mention
of recent mathematical modeling supporting the general superiority of combination
therapy. Several novel examples involving folate antagonists are proposed.Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma 757Madeleine DuvicCutaneous T-cell lymphomas (CTCLs) are non-Hodgkin’s T-cell lymphomas that
present as skin lesions. Mycosis fungoides with large cell transformation has a
5-year overall survival of 32% with involved skin and 7% with extracutaneous
involvement. Failure to cure advanced MF with large cell transformation and periph-
eral T-cell lymphoma has resulted in a search for novel targeted agents including an-
tibodies and gene modulators. Histone deacetylase inhibitors are small molecules
that seem to be particularly active for T-cell lymphoma.Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Se´zary
Syndrome 765John A. ZicExtracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to
an expansion of peripheral blood dendritic cell populations and an enhanced TH1 im-
mune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side
effect profile and moderate efficacy, ECP is considered first-line therapy for erythro-
dermic mycosis fungoides (MF) and Se´zary syndrome. Patients with a measurable
but low blood tumor burden are most likely to respond to ECP, and the addition of
adjunctive immunostimulatory agents may also increase response rates. There may
be a role for ECP in the treatment of refractory early stage MF, but data are limited.Monoclonal Antibodies 777Larisa J. GeskinUse of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Ap-
proaches targeting specific cellular targets on the malignant cells and in tumor
microenvironment have proven to be successful in hematologic malignancies,
including cutaneous lymphomas. mAb-based therapy for cutaneous T-cell lym-
phoma has demonstrated high response rates and a favorable toxicity profile in clin-
ical trials. Several antibodies and antibody-based conjugates are approved for use
in clinical practice, and many more are in ongoing and planned clinical trials. In addi-
tion, these safe and effective drugs can be used as pillars for sequential therapies in
a rational stepwise manner.Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma 787Catherine G. Chung and Brian PoligoneTraditional chemotherapies, interleukins, phosphorylase inhibitors, and protea-
some inhibitors are important therapies available to patients with cutaneous
T-cell lymphoma (CTCL). Traditional chemotherapies, both in combination and as
single agents, are commonly used in relapsed, refractory CTCLs that behave in
Contentsviiian aggressive manner. Interleukins, phosphorylase inhibitors, and proteasome in-
hibitors are less commonly used but data support a role in patients with more re-
fractory disease.Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Se´zary Syndrome 807Pooja Virmani, Jasmine Zain, Steven T. Rosen, Patricia L. Myskowski, and Christiane QuerfeldMycosis fungoides (MF) and Se´zary syndrome (SS) are common types of primary
cutaneous T-cell lymphoma. Early-stage MF has a favorable prognosis and re-
sponds well to skin-directed regimens. Patients with advanced-stage MF, trans-
formed MF, and SS are treated with combined systemic and skin-directed
therapies. However, the disease is incurable with standard regimens, and frequent
relapses are common. Owing to the lack of improvement in overall survival with stan-
dard regimens, hematopoietic stem cell transplant (HSCT) has been explored as a
potential curative option. This article reviews the role of HSCT in MF/SS and dis-
cusses data regarding conditioning regimens, treatment-related complications,
and outcomes.Practical Management of CD30+ Lymphoproliferative Disorders 819Lauren C. HugheyPrimary cutaneous CD30+ lymphoproliferative disorders (LPDs) account for approx-
imately 25% of cutaneous lymphomas. Although these LPDs are clinically heteroge-
neous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely
requires systemic treatment; however, multifocal primary cutaneous anaplastic
large cell cutaneous lymphoma and large cell transformation of mycosis fungoides
are typically treated systemically. As CD30+ LPDs are rare, there is little published
evidence to support a specific treatment algorithm. Most studies are case reports,
small case series, or retrospective reviews. This article discusses various treatment
choices for each of the CD30+ disorders and offers practical pearls to aid in choosing
an appropriate regimen.Diagnosis and Management of Cutaneous B-Cell Lymphoma 835Lauren C. Pinter-BrownThe diagnosis of primary cutaneous B-cell lymphoma (CBCL) requires that the
search for a more widespread lymphoma has been negative. The clinical presenta-
tion, outlook, and treatment options of the common types of CBCLs, with emphasis
on differences or similarities to their nodal counterparts, are discussed. Treatment
may range from observation to topical therapies to systemic therapies, depending
on the histology, degree and area of skin involvement, patient performance, and co-
morbidities. Rare lymphomas, such as intravascular large B-cell lymphoma and Ep-
stein-Barr virus–positive cutaneous lymphoproliferations that are associated with
immunodeficiency, are also briefly described.Index 841
